ArticleExperimental and therapeutic medicine2026
Sanguinarine chloride inducing ferroptosis and downregulating GPX4 expression in liver cancer: An integrated
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis, an iron-dependent form of regulated cell death driven by excessive lipid peroxidation, has been increasingly implicated in the development and progression of liver cancer. Despite sanguinarine chloride (SC) exhibiting antitumor activity in a number of cancer models, whether it modulates ferroptosis in liver cancer remains unclear. The present study systematically investigated the ferroptosis-inducing effects of SC and the underlying molecular mechanisms in liver cancer. Molecular docking and molecular dynamics simulations suggested that SC interacts with glutathione peroxidase 4 (GPX4) with favorable affinity and forms a stable complex. Functional assays showed that SC significantly inhibited proliferation and reduced the viability of HepG2 and Huh7 cells. Mechanistically, SC markedly decreased GPX4 protein expression, leading to the accumulation of lipid reactive oxygen species and malondialdehyde, together with characteristic mitochondrial changes associated with ferroptosis, including increased membrane density and loss of cristae. SC-induced cell death was partially rescued by the ferroptosis inhibitors ferrostatin-1 and deferoxamine, further supporting the involvement of ferroptosis. Consistently, in a xenograft model, SC suppressed GPX4 expression, promoted ferroptosis and significantly inhibited tumor growth. Collectively, these findings indicate that SC exerts antitumor effects in liver cancer, at least in part, by inducing ferroptosis through GPX4 downregulation, supporting further investigation of SC as a potential therapeutic candidate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.